Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumor · Hepatocellular Carcinoma

Coherus Oncology

Coherus Oncology patent portfolio — 73 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US HQ
2010 Founded
212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US
Founded
2010
Employees
212
Programs
25
Drugs
11
Patents
73
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Coherus Oncology patents

73 pharmaceutical patents indexed for Coherus Oncology. 0 expire within 24 months.

Coherus Oncology has 73 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

73 patents

Patent portfolio

Page 2 of 2

  1. US 9943601

    Etanercept formulations stabilized with combinations of sugars and polyols

    Expires Mon Apr 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9861695

    Stable aqueous formulations of adalimumab

    Expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9808525

    Stable aqueous formulations of adalimumab

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9801942

    Etanercept formulations stabilized with metal ions

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9789185

    Stable aqueous formulations of adalimumab

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9782480

    Stable aqueous formulations of adalimumab

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9782479

    Stable aqueous formulations of adalimumab

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9770510

    Etanercept formulations stabilized with xylitol

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9770507

    Stable aqueous formulations of adalimumab

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9765139

    Perfusion method for manufacturing etanercept

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9757454

    Stable aqueous formulations of adalimumab

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9737600

    Stable aqueous formulations of adalimumab

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9731008

    Stable aqueous formulations of adalimumab

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9731009

    Stable aqueous formulations of adalimumab

    Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9724414

    Stable aqueous formulations of adalimumab

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9724415

    Stable aqueous formulations of adalimumab

    Expires Mon Aug 03 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9707293

    Stable aqueous formulations of adalimumab

    Expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9682145

    Stable aqueous formulations of adalimumab

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9662396

    Stable aqueous formulations of etanercept

    Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9393305

    Etanercept formulations stabilized with xylitol

    Expires Mon Jul 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9382317

    Stable aqueous formulations of adalimumab

    Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9346880

    Stable aqueous formulations of adalimumab

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9340611

    Stable aqueous formulations of adalimumab

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9340612

    Stable aqueous formulations of adalimumab

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9302002

    Etanercept formulations stabilized with combinations of sugars and polyols

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Coherus Oncology have?

73 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Coherus Oncology patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.